RESMED News & Analysis

Niche play with more growth potential than many investors give it credit for.

Solid device sales with shares moderately undervalued.

Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.

Solid global sales and margin expansion are highlights from latest quarter.

With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors

Shares are up 25% year to date but still screen as undervalued.

Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.

Strong device sales and rebound in margin.

Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.

Shares rose after strong earnings report but remain materially undervalued.